ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MIRM Mirum Pharmaceuticals Inc

23.81
-0.04 (-0.17%)
Last Updated: 12:20:20
Delayed by 15 minutes

Period:

Draw Mode:

Volume 57,086
Bid Price 23.79
Ask Price 23.83
News -
Day High 24.06

Low
23.29

52 Week Range

High
35.56

Day Low 23.29
Company Name Stock Ticker Symbol Market Type
Mirum Pharmaceuticals Inc MIRM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -0.17% 23.81 12:20:20
Open Price Low Price High Price Close Price Prev Close
23.73 23.29 24.06 23.85
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,884 57,086 $ 23.73 $ 1,354,458 - 23.29 - 35.56
Last Trade Time Type Quantity Stock Price Currency
12:20:20 100 $ 23.81 USD

Mirum Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.11B 46.61M - 186.37M -163.42M -3.51 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mirum Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MIRM Message Board. Create One! See More Posts on MIRM Message Board See More Message Board Posts

Historical MIRM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week25.5126.01523.2924.41363,813-1.70-6.66%
1 Month27.2327.4123.2925.32450,986-3.42-12.56%
3 Months26.5030.2323.2926.98507,543-2.69-10.15%
6 Months27.8435.5623.2928.73593,822-4.03-14.48%
1 Year25.9935.5623.2928.30560,022-2.18-8.39%
3 Years18.4235.5612.8224.91354,0225.3929.26%
5 Years13.0035.566.512623.54278,60410.8183.15%

Mirum Pharmaceuticals Description

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Your Recent History

Delayed Upgrade Clock